New smart drug targets tough cancers in early human test
NCT ID NCT06805825
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests a new drug called NN3201 in people with advanced cancers that have a specific marker called c-Kit. The drug is designed to deliver a chemotherapy agent directly to cancer cells, potentially killing them while sparing healthy tissue. The study will enroll 67 participants with cancers like gastrointestinal stromal tumors, small-cell lung cancer, and others, to find a safe dose and check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NN3201 (an antibody-drug conjugate that targets c-Kit and delivers a chemotherapy drug directly to cancer cells)
- What this could lead to
- If it works, this could point toward a new treatment option for several hard-to-treat cancers that have a specific marker called c-Kit.
- What could go wrong
- This is a very early Phase 1 trial with only 67 people, focused on safety and dosing. It may not show strong anti-tumor effects, and side effects from the drug could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Case Comprehensive Cancer Center
RECRUITINGCleveland, Ohio, 44106, United States
-
NEXT Virginia
ACTIVE_NOT_RECRUITINGFairfax, Virginia, 22031, United States
-
Oregon Health & Science University
RECRUITINGPortland, Oregon, 97239, United States
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
University of Michigan Hospitals
RECRUITINGAnn Arbor, Michigan, 48109-9001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donor immune cells boost lung cancer remission?
- Could adding chest radiation extend life in advanced lung cancer?
- Can tracking a rare eye cancer pave the way for new treatments?
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?
- Can a new drug tame advanced solid tumors?